← Patent-cliff monitor small molecule LIVMARLI MARALIXIBAT CHLORIDE
Loss of exclusivity February 2040 latest FDA-listed patent expiry
Drug detail Brand name LIVMARLI Active ingredient MARALIXIBAT CHLORIDE Strength EQ 9.5MG BASE/ML Dosage form SOLUTION Route ORAL Modality Small molecule FDA approval September 2021 Marketing status RX
Listed patents Patent Expires Type 12599602 February 2040 use U-3290 11918578 February 2040 use U-3974 11229647 February 2040 use U-3290 11497745 February 2040 use U-3290 10512657 October 2032 use U-3850 11229661 October 2032 use U-3850 11376251 October 2032 use U-3974 11260053 May 2031 use U-3290
Regulatory exclusivity Code Expires ODE-471 March 2031 ODE-429 March 2030 ODE-379 September 2028 I-938 March 2027 NCE September 2026 NPP March 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.